Hineline J. Lawrence's Insider Trades & SAST Disclosures
Hineline J. Lawrence's most recent trade in Intra-Cellular Therapies Inc was a trade of 6,618 Common Stock done at an average price of $66.9 . Disclosure was reported to the exchange on March 7, 2024.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Hineline J. Lawrence.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
Showing you 100 results sorted by most recent dates.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Intra-Cellular Therapies Inc | Lawrence J. Hineline | SVP of Finance, CFO | Sale of securities on an exchange or to another person at price $ 66.93 per share. | 07 Mar 2024 | 6,618 | 0 (0%) | 0% | 66.9 | 442,943 | Common Stock |
| Intra-Cellular Therapies Inc | Lawrence J. Hineline | SVP of Finance, CFO | Sale of securities on an exchange or to another person at price $ 66.26 per share. | 07 Mar 2024 | 6,514 | 6,618 (0%) | 0% | 66.3 | 431,618 | Common Stock |
| Intra-Cellular Therapies Inc | Lawrence J. Hineline | SVP of Finance, CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Mar 2024 | 5,582 | 5,582 (0%) | 0% | - | Common Stock | |
| Intra-Cellular Therapies Inc | Lawrence J. Hineline | SVP of Finance, CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Mar 2024 | 5,582 | 5,582 | - | - | Restricted Stock Units | |
| Intra-Cellular Therapies Inc | Lawrence J. Hineline | SVP of Finance, CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 56.73 per share. | 07 Mar 2024 | 4,539 | 4,539 (0%) | 0% | 56.7 | 257,497 | Common Stock |
| Intra-Cellular Therapies Inc | Lawrence J. Hineline | SVP of Finance, CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Mar 2024 | 4,539 | 4,539 | - | - | Stock Option (right to purchase) | |
| Intra-Cellular Therapies Inc | Lawrence J. Hineline | SVP of Finance, CFO | Sale of securities on an exchange or to another person at price $ 66.47 per share. | 07 Mar 2024 | 4,475 | 64 (0%) | 0% | 66.5 | 297,453 | Common Stock |
| Intra-Cellular Therapies Inc | Lawrence J. Hineline | SVP of Finance, CFO | Sale of securities on an exchange or to another person at price $ 65.28 per share. | 07 Mar 2024 | 4,453 | 1,129 (0%) | 0% | 65.3 | 290,692 | Common Stock |
| Intra-Cellular Therapies Inc | Lawrence J. Hineline | SVP of Finance, CFO | Sale of securities on an exchange or to another person at price $ 66.54 per share. | 07 Mar 2024 | 1,100 | 29 (0%) | 0% | 66.5 | 73,194 | Common Stock |
| Intra-Cellular Therapies Inc | Lawrence J. Hineline | SVP of Finance, CFO | Sale of securities on an exchange or to another person at price $ 67.12 per share. | 07 Mar 2024 | 64 | 0 (0%) | 0% | 67.1 | 4,296 | Common Stock |
| Intra-Cellular Therapies Inc | Lawrence J. Hineline | SVP of Finance, CFO | Sale of securities on an exchange or to another person at price $ 67.31 per share. | 07 Mar 2024 | 29 | 0 (0%) | 0% | 67.3 | 1,952 | Common Stock |
| Intra-Cellular Therapies Inc | Lawrence J. Hineline | SVP of Finance, CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Mar 2024 | 13,132 | 26,266 | - | - | Restricted Stock Units | |
| Intra-Cellular Therapies Inc | Lawrence J. Hineline | SVP of Finance, CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Mar 2024 | 13,132 | 13,132 (0%) | 0% | - | Common Stock | |
| Intra-Cellular Therapies Inc | Lawrence J. Hineline | SVP of Finance, CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 26,227 | 26,227 | - | - | Restricted Stock Units | |
| Intra-Cellular Therapies Inc | J. Lawrence Hineline | SVP of Finance, CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Feb 2024 | 7,455 | 0 | - | - | Restricted Stock Units | |
| Intra-Cellular Therapies Inc | Hineline J. Lawrence | SVP of Finance, CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Feb 2024 | 7,455 | 7,455 (0%) | 0% | - | Common Stock | |
| Intra-Cellular Therapies Inc | Lawrence Hineline J. | SVP of Finance, CFO | Sale of securities on an exchange or to another person at price $ 69.38 per share. | 23 Feb 2024 | 6,867 | 288 (0%) | 0% | 69.4 | 476,432 | Common Stock |
| Intra-Cellular Therapies Inc | Lawrence J. Hineline | SVP of Finance, CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Feb 2024 | 5,882 | 0 | - | - | Stock Option (right to buy) | |
| Intra-Cellular Therapies Inc | J. Hineline Lawrence | SVP of Finance, CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 36.89 per share. | 23 Feb 2024 | 5,882 | 5,882 (0%) | 0% | 36.9 | 216,987 | Common Stock |
| Intra-Cellular Therapies Inc | J. Lawrence Hineline | SVP of Finance, CFO | Sale of securities on an exchange or to another person at price $ 69.47 per share. | 23 Feb 2024 | 5,282 | 600 (0%) | 0% | 69.5 | 366,941 | Common Stock |
| Intra-Cellular Therapies Inc | Hineline J. Lawrence | SVP of Finance, CFO | Sale of securities on an exchange or to another person at price $ 69.81 per share. | 23 Feb 2024 | 600 | 0 (0%) | 0% | 69.8 | 41,886 | Common Stock |
| Intra-Cellular Therapies Inc | Lawrence J. Hineline | SVP of Finance, CFO | Sale of securities on an exchange or to another person at price $ 68.33 per share. | 23 Feb 2024 | 300 | 7,155 (0%) | 0% | 68.3 | 20,499 | Common Stock |
| Intra-Cellular Therapies Inc | J. Lawrence Hineline | SVP of Finance, CFO | Sale of securities on an exchange or to another person at price $ 70.15 per share. | 23 Feb 2024 | 288 | 0 (0%) | 0% | 70.1 | 20,203 | Common Stock |
| Intra-Cellular Therapies Inc | Lawrence Hineline J. | SVP of Finance, CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2024 | 11,183 | 11,183 (0%) | 0% | 0 | Common Stock | |
| Intra-Cellular Therapies Inc | Lawrence J. Hineline | SVP of Finance, CFO | Sale of securities on an exchange or to another person at price $ 66.61 per share. | 01 Feb 2024 | 10,998 | 185 (0%) | 0% | 66.6 | 732,577 | Common Stock |
| Intra-Cellular Therapies Inc | J. Hineline Lawrence | SVP of Finance, CFO | Sale of securities on an exchange or to another person at price $ 67.35 per share. | 01 Feb 2024 | 185 | 0 (0%) | 0% | 67.4 | 12,460 | Common Stock |
| Intra-Cellular Therapies Inc | Lawrence J. Hineline | SVP of Finance CFO | Sale of securities on an exchange or to another person at price $ 64.37 per share. | 14 Jun 2023 | 44,035 | 3,592 (0%) | 0% | 64.4 | 2,834,533 | Common Stock |
| Intra-Cellular Therapies Inc | Lawrence J. Hineline | SVP of Finance CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Jun 2023 | 40,472 | 0 | - | - | Stock Option (right to purchase) | |
| Intra-Cellular Therapies Inc | Lawrence J. Hineline | SVP of Finance CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 53.63 per share. | 14 Jun 2023 | 40,472 | 40,472 (0%) | 0% | 53.6 | 2,170,513 | Common Stock |
| Intra-Cellular Therapies Inc | Lawrence J. Hineline | SVP of Finance CFO | Sale of securities on an exchange or to another person at price $ 63.35 per share. | 14 Jun 2023 | 34,227 | 47,627 (0%) | 0% | 63.3 | 2,168,280 | Common Stock |
| Intra-Cellular Therapies Inc | Lawrence J. Hineline | SVP of Finance CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Jun 2023 | 25,082 | 0 | - | - | Stock Option (right to purchase) | |
| Intra-Cellular Therapies Inc | Lawrence J. Hineline | SVP of Finance CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 23.94 per share. | 14 Jun 2023 | 25,082 | 65,554 (0%) | 0% | 23.9 | 600,463 | Common Stock |
| Intra-Cellular Therapies Inc | Lawrence J. Hineline | SVP of Finance CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Jun 2023 | 11,762 | 5,882 | - | - | Stock Option (right to purchase) | |
| Intra-Cellular Therapies Inc | Lawrence J. Hineline | SVP of Finance CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 36.89 per share. | 14 Jun 2023 | 11,762 | 77,316 (0%) | 0% | 36.9 | 433,900 | Common Stock |
| Intra-Cellular Therapies Inc | Lawrence J. Hineline | SVP of Finance CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Jun 2023 | 4,538 | 9,078 | - | - | Stock Option (right to purchase) | |
| Intra-Cellular Therapies Inc | Lawrence J. Hineline | SVP of Finance CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 56.73 per share. | 14 Jun 2023 | 4,538 | 81,854 (0%) | 0% | 56.7 | 257,441 | Common Stock |
| Intra-Cellular Therapies Inc | Lawrence J. Hineline | SVP of Finance CFO | Sale of securities on an exchange or to another person at price $ 65.01 per share. | 14 Jun 2023 | 3,592 | 0 (0%) | 0% | 65.0 | 233,516 | Common Stock |
| Intra-Cellular Therapies Inc | Lawrence J. Hineline | SVP of Finance CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Mar 2023 | 15,663 | 15,663 (0%) | 0% | 0 | Common Stock | |
| Intra-Cellular Therapies Inc | Lawrence J. Hineline | SVP of Finance CFO | Sale of securities on an exchange or to another person at price $ 43.17 per share. | 09 Mar 2023 | 12,963 | 2,700 (0%) | 0% | 43.2 | 559,613 | Common Stock |
| Intra-Cellular Therapies Inc | Lawrence J. Hineline | SVP of Finance CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Mar 2023 | 5,582 | 11,164 | - | - | Restricted Stock Units | |
| Intra-Cellular Therapies Inc | Lawrence J. Hineline | SVP of Finance CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Mar 2023 | 5,582 | 5,582 (0%) | 0% | - | Common Stock | |
| Intra-Cellular Therapies Inc | Lawrence J. Hineline | SVP of Finance CFO | Sale of securities on an exchange or to another person at price $ 44.97 per share. | 09 Mar 2023 | 5,324 | 258 (0%) | 0% | 45.0 | 239,420 | Common Stock |
| Intra-Cellular Therapies Inc | Lawrence J. Hineline | SVP of Finance CFO | Sale of securities on an exchange or to another person at price $ 42.52 per share. | 09 Mar 2023 | 2,700 | 0 (0%) | 0% | 42.5 | 114,804 | Common Stock |
| Intra-Cellular Therapies Inc | Lawrence J. Hineline | SVP of Finance CFO | Sale of securities on an exchange or to another person at price $ 44.14 per share. | 09 Mar 2023 | 258 | 0 (0%) | 0% | 44.1 | 11,388 | Common Stock |
| Intra-Cellular Therapies Inc | Lawrence J. Hineline | SVP of Finance CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2023 | 39,398 | 39,398 | - | - | Restricted Stock Units | |
| Intra-Cellular Therapies Inc | Lawrence J. Hineline | SVP of Finance CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Feb 2023 | 7,455 | 7,455 (0%) | 0% | - | Common Stock | |
| Intra-Cellular Therapies Inc | Lawrence J. Hineline | SVP of Finance CFO | Sale of securities on an exchange or to another person at price $ 47.03 per share. | 23 Feb 2023 | 7,455 | 0 (0%) | 0% | 47.0 | 350,609 | Common Stock |
| Intra-Cellular Therapies Inc | Lawrence J. Hineline | SVP of Finance CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Feb 2023 | 7,455 | 7,455 | - | - | Restricted Stock Units | |
| Intra-Cellular Therapies Inc | Lawrence J. Hineline | SVP of Finance CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 12.73 per share. | 18 Feb 2023 | 53,968 | 53,968 (0%) | 0% | 12.7 | 687,013 | Common Stock |
| Intra-Cellular Therapies Inc | Lawrence J. Hineline | SVP of Finance CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Feb 2023 | 53,968 | 0 | - | - | Stock Option (right to buy) | |
| Intra-Cellular Therapies Inc | Lawrence J. Hineline | SVP of Finance CFO | Sale of securities on an exchange or to another person at price $ 49.81 per share. | 18 Feb 2023 | 52,279 | 1,689 (0%) | 0% | 49.8 | 2,604,017 | Common Stock |
| Intra-Cellular Therapies Inc | Lawrence J. Hineline | SVP of Finance CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Feb 2023 | 10,443 | 0 | - | - | Restricted Stock Units | |
| Intra-Cellular Therapies Inc | Lawrence J. Hineline | SVP of Finance CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Feb 2023 | 10,443 | 10,443 (0%) | 0% | - | Common Stock | |
| Intra-Cellular Therapies Inc | Lawrence J. Hineline | SVP of Finance CFO | Sale of securities on an exchange or to another person at price $ 46.54 per share. | 18 Feb 2023 | 8,649 | 1,794 (0%) | 0% | 46.5 | 402,524 | Common Stock |
| Intra-Cellular Therapies Inc | Lawrence J. Hineline | SVP of Finance CFO | Sale of securities on an exchange or to another person at price $ 50.59 per share. | 18 Feb 2023 | 1,689 | 0 (0%) | 0% | 50.6 | 85,447 | Common Stock |
| Intra-Cellular Therapies Inc | Lawrence J. Hineline | SVP of Finance CFO | Sale of securities on an exchange or to another person at price $ 48.72 per share. | 18 Feb 2023 | 900 | 94 (0%) | 0% | 48.7 | 43,848 | Common Stock |
| Intra-Cellular Therapies Inc | Lawrence J. Hineline | SVP of Finance CFO | Sale of securities on an exchange or to another person at price $ 47.32 per share. | 18 Feb 2023 | 800 | 994 (0%) | 0% | 47.3 | 37,856 | Common Stock |
| Intra-Cellular Therapies Inc | Lawrence J. Hineline | SVP of Finance CFO | Sale of securities on an exchange or to another person at price $ 49.60 per share. | 18 Feb 2023 | 94 | 0 (0%) | 0% | 49.6 | 4,662 | Common Stock |
| Intra-Cellular Therapies Inc | Lawrence J. Hineline | SVP of Finance CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2022 | 16,746 | 16,746 | - | - | Restricted Stock Units | |
| Intra-Cellular Therapies Inc | Lawrence J. Hineline | SVP of Finance CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2022 | 13,616 | 13,616 | - | - | Stock Option (right to buy) | |
| Intra-Cellular Therapies Inc | Lawrence J. Hineline | SVP of Finance CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Feb 2022 | 10,443 | 10,443 | - | - | Restricted Stock Units | |
| Intra-Cellular Therapies Inc | Lawrence J. Hineline | SVP of Finance CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Feb 2022 | 10,443 | 10,443 (0%) | 0% | - | Common Stock | |
| Intra-Cellular Therapies Inc | Lawrence J. Hineline | SVP of Finance CFO | Sale of securities on an exchange or to another person at price $ 55.72 per share. | 18 Feb 2022 | 5,816 | 4,627 (0%) | 0% | 55.7 | 324,068 | Common Stock |
| Intra-Cellular Therapies Inc | Lawrence J. Hineline | SVP of Finance CFO | Sale of securities on an exchange or to another person at price $ 54.99 per share. | 18 Feb 2022 | 4,627 | 0 (0%) | 0% | 55.0 | 254,439 | Common Stock |
| Intra-Cellular Therapies Inc | Lawrence J. Hineline | SVP of Finance CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Jan 2022 | 19,639 | 0 | - | - | Restricted Stock Units | |
| Intra-Cellular Therapies Inc | Lawrence J. Hineline | SVP of Finance CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Jan 2022 | 19,639 | 19,639 (0%) | 0% | - | Common Stock | |
| Intra-Cellular Therapies Inc | Lawrence J. Hineline | SVP of Finance CFO | Sale of securities on an exchange or to another person at price $ 40.77 per share. | 08 Jan 2022 | 12,434 | 4,100 (0%) | 0% | 40.8 | 506,934 | Common Stock |
| Intra-Cellular Therapies Inc | Lawrence J. Hineline | SVP of Finance CFO | Sale of securities on an exchange or to another person at price $ 40.07 per share. | 08 Jan 2022 | 4,100 | 0 (0%) | 0% | 40.1 | 164,287 | Common Stock |
| Intra-Cellular Therapies Inc | Lawrence J. Hineline | SVP of Finance CFO | Sale of securities on an exchange or to another person at price $ 41.61 per share. | 08 Jan 2022 | 3,105 | 16,534 (0%) | 0% | 41.6 | 129,199 | Common Stock |
| Intra-Cellular Therapies Inc | Lawrence J. Hineline | SVP of Finance CFO | Sale of securities on an exchange or to another person at price $ 47.84 per share. | 21 Dec 2021 | 100,803 | 48,735 (0%) | 0% | 47.8 | 4,822,416 | Common Stock |
| Intra-Cellular Therapies Inc | Lawrence J. Hineline | SVP of Finance CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 17.57 per share. | 21 Dec 2021 | 72,120 | 122,120 (0%) | 0% | 17.6 | 1,267,148 | Common Stock |
| Intra-Cellular Therapies Inc | Lawrence J. Hineline | SVP of Finance CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Dec 2021 | 72,120 | 0 | - | - | Stock Option (right to buy) | |
| Intra-Cellular Therapies Inc | Lawrence J. Hineline | SVP of Finance CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Dec 2021 | 52,880 | 10,837 | - | - | Stock Option (right to buy) | |
| Intra-Cellular Therapies Inc | Lawrence J. Hineline | SVP of Finance CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 15.73 per share. | 21 Dec 2021 | 52,880 | 175,000 (0%) | 0% | 15.7 | 831,802 | Common Stock |
| Intra-Cellular Therapies Inc | Lawrence J. Hineline | SVP of Finance CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 16.86 per share. | 21 Dec 2021 | 50,000 | 50,000 (0%) | 0% | 16.9 | 843,000 | Common Stock |
| Intra-Cellular Therapies Inc | Lawrence J. Hineline | SVP of Finance CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Dec 2021 | 50,000 | 0 | - | - | Stock Option (right to buy) | |
| Intra-Cellular Therapies Inc | Lawrence J. Hineline | SVP of Finance CFO | Sale of securities on an exchange or to another person at price $ 46.91 per share. | 21 Dec 2021 | 35,135 | 13,600 (0%) | 0% | 46.9 | 1,648,183 | Common Stock |
| Intra-Cellular Therapies Inc | Lawrence J. Hineline | SVP of Finance CFO | Sale of securities on an exchange or to another person at price $ 48.67 per share. | 21 Dec 2021 | 25,462 | 149,538 (0%) | 0% | 48.7 | 1,239,236 | Common Stock |
| Intra-Cellular Therapies Inc | Lawrence J. Hineline | SVP of Finance CFO | Sale of securities on an exchange or to another person at price $ 45.81 per share. | 21 Dec 2021 | 9,200 | 4,400 (0%) | 0% | 45.8 | 421,452 | Common Stock |
| Intra-Cellular Therapies Inc | Lawrence J. Hineline | SVP of Finance CFO | Sale of securities on an exchange or to another person at price $ 44.95 per share. | 21 Dec 2021 | 3,800 | 600 (0%) | 0% | 45.0 | 170,810 | Common Stock |
| Intra-Cellular Therapies Inc | Lawrence J. Hineline | SVP of Finance CFO | Sale of securities on an exchange or to another person at price $ 44.28 per share. | 21 Dec 2021 | 600 | 0 (0%) | 0% | 44.3 | 26,568 | Common Stock |
| Intra-Cellular Therapies Inc | Lawrence J. Hineline | SVP of Finance CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2021 | 22,364 | 22,364 | - | - | Restricted Stock Units | |
| Intra-Cellular Therapies Inc | Lawrence J. Hineline | SVP of Finance CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2021 | 17,644 | 17,644 | - | - | Stock Option (right to buy) | |
| Intra-Cellular Therapies Inc | Lawrence J. Hineline | SVP of Finance CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Feb 2021 | 10,442 | 20,886 | - | - | Restricted Stock Units | |
| Intra-Cellular Therapies Inc | Lawrence J. Hineline | SVP of Finance CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Feb 2021 | 10,442 | 10,442 (0%) | 0% | - | Common Stock | |
| Intra-Cellular Therapies Inc | Lawrence J. Hineline | SVP of Finance CFO | Sale of securities on an exchange or to another person at price $ 39.27 per share. | 18 Feb 2021 | 9,242 | 1,200 (0%) | 0% | 39.3 | 362,933 | Common Stock |
| Intra-Cellular Therapies Inc | Lawrence J. Hineline | SVP of Finance CFO | Sale of securities on an exchange or to another person at price $ 38.91 per share. | 18 Feb 2021 | 1,200 | 0 (0%) | 0% | 38.9 | 46,692 | Common Stock |
| Intra-Cellular Therapies Inc | Lawrence J. Hineline | SVP of Finance CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Jan 2021 | 19,638 | 19,638 (0%) | 0% | - | Common Stock | |
| Intra-Cellular Therapies Inc | Lawrence J. Hineline | SVP of Finance CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Jan 2021 | 19,638 | 19,639 | - | - | Restricted Stock Units | |
| Intra-Cellular Therapies Inc | Lawrence J. Hineline | SVP of Finance CFO | Sale of securities on an exchange or to another person at price $ 32.07 per share. | 08 Jan 2021 | 17,262 | 2,376 (0%) | 0% | 32.1 | 553,592 | Common Stock |
| Intra-Cellular Therapies Inc | Lawrence J. Hineline | SVP of Finance CFO | Sale of securities on an exchange or to another person at price $ 31.64 per share. | 08 Jan 2021 | 2,376 | 0 (0%) | 0% | 31.6 | 75,177 | Common Stock |
| Intra-Cellular Therapies Inc | Lawrence J. Hineline | SVP of Finance CFO | Gift of securities by or to the insider at price $ 0.00 per share. | 08 Jan 2021 | 350 | 0 (0%) | 0% | 0 | Common Stock | |
| Intra-Cellular Therapies Inc | Lawrence J. Hineline | SVP of Finance CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2021 | 16,160 | 0 | - | - | Restricted Stock Units | |
| Intra-Cellular Therapies Inc | Lawrence J. Hineline | SVP of Finance CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2021 | 16,160 | 16,160 (0%) | 0% | - | Common Stock | |
| Intra-Cellular Therapies Inc | Lawrence J. Hineline | SVP of Finance CFO | Sale of securities on an exchange or to another person at price $ 31.40 per share. | 03 Jan 2021 | 12,710 | 3,450 (0%) | 0% | 31.4 | 399,094 | Common Stock |
| Intra-Cellular Therapies Inc | Lawrence J. Hineline | SVP of Finance CFO | Sale of securities on an exchange or to another person at price $ 30.94 per share. | 03 Jan 2021 | 3,100 | 350 (0%) | 0% | 30.9 | 95,914 | Common Stock |
| Intra-Cellular Therapies Inc | Lawrence J. Hineline | SVP of Finance CFO | Sale of securities on an exchange or to another person at price $ 25.41 per share. | 11 Nov 2020 | 28,034 | 0 (0%) | 0% | 25.4 | 712,344 | Common Stock |
| Intra-Cellular Therapies Inc | Lawrence J. Hineline | SVP of Finance CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.26 per share. | 11 Nov 2020 | 10,000 | 28,034 (0%) | 0% | 3.3 | 32,600 | Common Stock |
| Intra-Cellular Therapies Inc | Lawrence J. Hineline | SVP of Finance CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Nov 2020 | 10,000 | 0 | - | - | Stock Option (right to buy) | |
| Intra-Cellular Therapies Inc | Lawrence J. Hineline | SVP of Finance CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Nov 2020 | 10,000 | 0 | - | - | Stock Option (right to buy) | |
| Intra-Cellular Therapies Inc | Lawrence J. Hineline | SVP of Finance CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.84 per share. | 11 Nov 2020 | 10,000 | 18,034 (0%) | 0% | 2.8 | 28,400 | Common Stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges